Search Results for: epithelioid

Understanding Treatment Options for Malignant Pleural Mesothelioma
| |

Understanding Treatment Options for Malignant Pleural Mesothelioma

Malignant pleural mesothelioma is a rare type of cancer and standard therapies are limited. Therefore, most patients consider one or more of three treatment options. These paths use different types of therapies and they are usually not exclusive. Mesothelioma patients can move from one type to another and, if their doctors agree, can sometimes use them in combination. A new publication gives an overview of the best treatment options currently available for malignant pleural mesothelioma. Standard therapies include chemotherapy, radiation, and surgery. If more than one of these therapies is used it is may be called multi-modality therapy. Oncologists are the doctors who provide chemo and radiation. Of course, surgeons provide surgeries. Understanding the Mesothelioma Diagnosis Malignant pleural mesothelioma is a…

Combining Cytology and Immunology for a Less Invasive Mesothelioma Diagnosis
| |

Combining Cytology and Immunology for a Less Invasive Mesothelioma Diagnosis

An invasive surgical or tissue biopsy is often required to get a definitive mesothelioma diagnosis. But a new hybrid exam might offer an alternative for mesothelioma patients. It involves the combination of cytology and immunology. Cytology tests look at the cells in body fluids. It is the analysis of a patient’s cells under a microscope. And immunology is the study of the immune system. Together, these two areas of science provide new hope for mesothelioma patients. The Tokyo Medical University in Japan has been looking into advanced diagnostic options. They believe that a combination of cytology and immunology methods can lead to a definitive diagnosis. This is good news for mesothelioma patients. It will mean a quicker mesothelioma diagnosis without…

New Mesothelioma Subtype Called Mesothelioma in Situ
|

New Mesothelioma Subtype Called Mesothelioma in Situ

The 2015 WHO classification of pleural mesothelioma included three histological subtypes. The new fourth mesothelioma subtype is called mesothelioma in situ. It is a very early form of mesothelioma. Previous studies suggest that it may be a precursor to invasive mesothelioma. If patients know they have it, they may have years to try to keep mesothelioma from developing. Pathologists can tell the difference between the subtypes by looking at the cells under a microscope. Each subtype has a slightly different cell shape, growth pattern, and nuclear characteristics. Four Subtypes of Mesothelioma Pleural mesothelioma is a very rare type of cancer. Only about 2,500 people in the US receive a mesothelioma diagnosis every year. Asbestos inhalation is the primary cause of pleural mesothelioma. Most people with pleural…

Using CT Scans in Surgical Decision-Making in Peritoneal Mesothelioma
|

Using CT Scans in Surgical Decision-Making in Peritoneal Mesothelioma

Peritoneal mesothelioma is caused by asbestos. The peritoneum is the space in your abdomen that contains the intestines, the stomach, and the liver. The abdomen (peritoneum) is the second most common site of mesothelioma after the pleural (lungs and chest). Most doctors believe peritoneal mesothelioma is caused by the ingestion of asbestos fibers. Microscopic asbestos fibers become embedded in the abdomen (peritoneum). After about 20-50 years, these fibers can cause inflammation and mutations in the healthy mesothelial cells. These mutations may ultimately cause these cells to become cancerous. Thus, forming tumors in the peritoneum. Patients diagnosed with peritoneal mesothelioma may survive several or more years after diagnosis. There are long-term survivors, such as Paul Kraus. Using CT Scans to Avoid…

Radiation Therapy for Mesothelioma Patients: Value and Timing
| | |

Radiation Therapy for Mesothelioma Patients: Value and Timing

The value and safety of radiation therapy for mesothelioma patients are promising. Oncologists from the Fox Chase Cancer Center released new data on radiotherapy. What are the options for radiation therapy? What is the best timing? Who should receive it? This guide shows the role of radiotherapy in the treatment of mesothelioma. Mesothelioma Radiosensitivity and Treatment Combinations Mesothelioma tumors are radiosensitive. This means they are sensitive to X-rays and radiant energy forms. In other words, mesothelioma tumors are treatable with radiation therapy. The use of a multi-modality treatment has also shown potential for mesothelioma patients. A tri-modality treatment uses three different treatment types. The combination of surgery, chemotherapy, and radiotherapy is most common. Understanding Timing and Adverse Effects There are…

Top Three Factors Predicting Mesothelioma Survival are Age, Histological Type, and Surgery Status
| | | |

Top Three Factors Predicting Mesothelioma Survival are Age, Histological Type, and Surgery Status

Malignant pleural mesothelioma is a rare and aggressive malignancy with a dismal prognosis. A new study is predicting mesothelioma survival among male and female patients in the United States. Identifying factors “associated with mesothelioma mortality is important research given the poor prognosis” according to Dr. Bian Liu from the a Icahn School of Medicine at Mount Sinai in New York. A new study applied a machine-learning algorithm to 12,210 patients to predict survival. The top three factors were age, histological type, and cancer-directed surgery status. Analyzing Over 12,000 Mesothelioma Patients Scientists from the New York State Department of Health included 12,210 mesothelioma patients. They involved only malignant pleural mesothelioma patients. They excluded cases with unknown diagnostic confirmation and unknown survival…

Treatment Options Improving in the ‘New Era’ for Mesothelioma
| |

Treatment Options Improving in the ‘New Era’ for Mesothelioma

Calling it a “new era” for malignant pleural mesothelioma, doctors from four of the nation’s top cancer centers have just published an update on treatment options for this rare disease.  The article was prepared by mesothelioma experts at MD Anderson Cancer Center in Texas, NYU Langone Medical Center, Memorial Sloan Kettering Cancer Center in New York and the Mayo Clinic in Minnesota.  The article in the Journal of Clinical Oncology highlights the recent FDA approvals of a new medical device and a new immunotherapy combination for pleural mesothelioma. The authors say these and other advances are “generating momentum” to find better mesothelioma therapies.  Tumor Treating Fields Changing the Game Pleural mesothelioma is fast-growing and difficult to treat. Mesothelioma rarely responds…

Lung-Sparing Surgery and Mesothelioma Survival

Lung-Sparing Surgery and Mesothelioma Survival

Italian researchers say lung-sparing surgery can lead to long-term mesothelioma survival, even if surgeons take a more conservative approach.  Lung-sparing surgery for mesothelioma is also known as pleurectomy with decortication (P/D). P/D surgery is less extensive than the other main surgical approach for mesothelioma but it is also less risky. Now, doctors at Venice-Mestre Hospital say that, as long as it is performed early enough and combined with other treatments, lung-sparing surgery saves lives. Their report in the Journal of Thoracic Disease details the outcomes of 155 mesothelioma surgery patients tracked for a median of a year-and-a-half.  Extrapleural Pneumonectomy & Lung-Sparing Surgery Extrapleural pneumonectomy (EPP) is the most radical operation for pleural mesothelioma. In addition to removing the mesothelioma tumor…

Expert Says Malignant Mesothelioma Research ‘Turned a Corner’ in 2021
| |

Expert Says Malignant Mesothelioma Research ‘Turned a Corner’ in 2021

An internationally-known mesothelioma specialist says 2021 has been one of the best years yet for malignant mesothelioma research, giving patients and their families more reason than ever to be hopeful.  Hedy Lee Kindler, MD, is Director of the University of Chicago Medical Center’s Mesothelioma Program. In a commentary in JCO Oncology Practice, Dr. Kindler says the outlook for mesothelioma sufferers this year is “far brighter than it has been for a very long time.” Dr. Kindler points to several recent advances in malignant mesothelioma research and treatment as reasons for optimism. The FDA approved the second systemic therapy for mesothelioma in late 2020. This year saw five positive mesothelioma clinical trials.  Kindler says these advances suggest that the future may…

New Mesothelioma Grading System: A Better Path to Prognosis?
| | |

New Mesothelioma Grading System: A Better Path to Prognosis?

A team of Australian researchers have developed a new mesothelioma grading system they believe is a more accurate method for predicting outcomes. The system assigns weighted scores based on things like mesothelioma subtype, the shape of the nuclei, BAP1 loss and other parameters. A higher score suggests the patient’s mesothelioma case may be more challenging to treat. Tests of the system in more than 350 patients show that it is highly accurate.  The team lays out their new mesothelioma grading system in a recent issue of the American Journal of Surgical Pathology. In the article, they make the case for why this new prognostic tool could be a helpful supplement to the current, more widely-used WHO system.  The Importance of…